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Abstract
Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at 
an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. 
Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there 
are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent 
EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge 
of the molecular abnormalities in EC have permitted the development of promising targeted therapies.
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Methodology
These guidelines have been developed by a multidisciplinary 
team of experts from  Spanish Ovarian Cancer Research 
Group (GEICO) and SEOM for gynecological malignan-
cies. First, each section was written by an expert and then 
all the authors discussed the results and determined the level 
of evidence and the grade of recommendation, according 
to the Infectious Diseases Society of America-US Public 
Health Service Grading System. The final text was reviewed 
and approved by all the authors. The goal of this document 
consists of providing clear practical recommendations about 
the management of endometrial cancer (EC).
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Introduction
EC is the most common gynecological cancer in developed 
countries. Although most EC patients have a favorable prog-
nosis, those either with high-risk early disease or advanced 
stage at diagnosis have a survival below 50%.
The most important risk factors identified in EC are obe-
sity, long-lasting endogenous or exogenous hyperestrogen-
ism (polycystic ovary, tamoxifen therapy, anovulation, and 
nulliparity), hypertension and diabetes mellitus. In addition, 
women with Lynch syndrome (LS, or hereditary nonpoly-
posis colon cancer) are at a markedly increased risk of EC.
Diagnosis
Abnormal uterine bleeding is the most frequent symptom of 
EC. Particular suspicion should be held for postmenopausal 
women or for those over 40 years with high-risk factors.
Transvaginal ultrasound (TVUS) is considered the first-
line imaging technique to be performed. In postmenopausal 
women, TVUS evaluation of the endometrial thickness has 
a high accuracy for EC diagnosis using a cut-off value of 
3 mm [II, B]. When an endometrial thickness is identified, 
an endometrial biopsy should be performed. Endometrial 
sampling is the gold standard for histologic diagnosis. If 
bleeding persists or recurs after endometrial sampling with 
benign findings, hysteroscopy should be performed.
The role of preoperative studies is to establish risk groups 
and to define the surgical management. A chest radiograph 
should be performed as a part of the initial assessment. Con-
trast-enhanced MRI is the best method for detecting myo-
metrial invasion or cervical involvement, when compared 
with non-enhanced MRI, ultrasound, or CT scan. MRI is 
also the best imaging modality, compared with CT or posi-
tron emission tomography (PET) with or without CT, for 
detecting lymph node metastases. There is no evidence for 
the clinical usefulness of CA 125 in the pretreatment evalu-
ation of EC [IV, B].
Hereditary endometrial cancer
The majority of ECs are associated with sporadic muta-
tions. The genetic mutations associated with LS are respon-
sible for 2–5% of all the ECs, mainly affected by the MLH1 
and MSH2 genes. The estimated lifetime risk of EC varies 
between 18% in MLH1 and 30% in MSH2 mutation carriers 
[1]. The Amsterdam II criteria and revised Bethesda Guide-
lines can be used to identify women with LS. The incidence 
of EC was significantly lower in the largest retrospective 
cohort study in women with the germline MLH1, MSH2 
or MSH6 mutation, who underwent risk-reducing surgery 
versus those who did not [2].
Molecular screening for LS should be performed in 
women with Amsterdam or Bethesda criteria and women 
with EC before 50 years [II, A]. Prophylactic surgery with 
hysterectomy and bilateral salpingo-oophorectomy should 
be offered in women with LS mutations who have completed 
childbearing [IV, B].
Screening
There are no high-quality data to support the efficacy of 
screening for reducing EC mortality.
Routine screening of asymptomatic women at average or 
increased risk of EC is not recommended [II, A]. In women 
with LS, screening should be offered in asymptomatic 
women who have not completed childbearing or women 
that refused prophylactic surgery beginning at the age of 
30–35 or 5–10 years prior the earliest age of first diagnosis 
of Lynch-associated cancer in the family. Annual endome-
trial sampling [II, A], TVUS with endometrial aspiration and 
serum CA 125 are usually recommended to be performed 
every year [IV, B].
Pathology and molecular biology 
of endometrial carcinoma
WHO’s classification of EC defines seven different types of 
tumor: endometrioid carcinoma (~ 80% of EC), usual type 
and variants, mucinous adenocarcinoma (1–9% of EC), 
serous carcinoma (< 10% of EC), clear cell carcinoma (< 5% 
of EC), neuroendocrine carcinoma, mixed carcinoma and 
undifferentiated and dedifferentiated carcinoma [3].
Endometrioid adenocarcinoma (EEC) and their variants 
are the prototype of type I EC. The usual type EEC encom-
passes a spectrum of neoplasms with variable histological 
differentiation that ranges from well-differentiated tumors 
(grades 1 and 2) to solid and poorly differentiated carcino-
mas (grade 3). EEC with squamous differentiation accounts 
for 25–50% of all EEC.
Serous carcinoma (SC) is the prototype of type II EC. 
SC is a very aggressive tumor, which arises occasionally 
in endometrial polyps. SC is usually associated with deep 
myometrial and extensive lymphovascular invasion. Tumor 
cells are usually positive for p53, p16, IMP2, IMP3.
Clear Cell Carcinoma (CCC ) shows clear cells and a 
combination of patterns such as solid, papillary, glandu-
lar, and tubulocystic. HNF-1 beta, AMACR and Napsin A 
immunostaining are usually expressed.
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SC or CCC may coexist with EEC. When more than one 
of these components is present at least in 5% of the tumor, 
it is diagnosed as a mixed carcinoma.
The molecular genetic alterations of EEC (type I) dif-
fer from those of SC (type II), and cDNA analysis shows 
different gene expression profiles. Whereas EEC shows 
microsatellite instability (MI) and mutations in the PTEN, 
PIK3CA, K-RAS and CTNNB1 genes, SC have alterations 
of p53, chromosomal instability, as well as other molecu-
lar alterations (STK15, p16, E-cadherin, and C-erbB2) [4] 
(Table 1).
The Cancer Genome Atlas Research Network (TCGA) 
has recently performed an integrating genomic charac-
terization of EC [5]. Interestingly, exome sequence analy-
sis revealed four groups of ECs: Group 1, with EEC with 
mutations in POLE, and showing high mutation rates 
(ultramutated), associated with good prognosis; Group 
2, including EEC with microsatellite instability (hyper-
mutated), and Group 3, tumors including EEC with low 
copy number alterations, showing similar progression-
free survival rates. Group 4 (serous-like) including SC, 
but also EEC (usually grade 3), exhibited p53 mutations, 
and worse prognosis. Results show that there is a group 
of EEC, that are molecularly and prognostically similar 
to SC. Combining POLE mutational analysis with immu-
nohistochemical analysis of p53 and mismatch repair 
markers (PMS-2 and MSH-6) have been proposed to clas-
sify the tumors in the four TCGA groups, particularly 
for high-grade EEC and SC, as a surrogate approach to 
apply TCGA to clinical practice. However, validation is 
needed.
Staging and risk assessment
EC is surgically staged. The staging is based on FIGO 2009 
(Table 2) [6]. The most important prognostic factors iden-
tified in EC are: FIGO stage, histological subtype, grade, 
depth of myometrial invasion, lymphovascular space inva-
sion (LVSI), and age [7]. According to the risk of relapse, 
EC has been subdivided into four risk categories (Table 3). 
In the near future, the molecular advances could be used for 




All patients with newly diagnosed disease should be con-
sidered for surgery.
The standard surgical approach of endometrioid EC in 
early stages is total hysterectomy without vaginal cuff with 
bilateral salpingo-oophorectomy and with or without lym-
phadenectomy. Peritoneal cytology, although recommended 
is not mandatory for FIGO staging.
Lymphadenectomy (LND) provides prognostic informa-
tion. Two randomized controlled trials have shown no over-
all survival (OS) benefit from LND in early-stage EC [8, 
9]. Decisions about whether to perform lymphadenectomy 
and to what extent can be made based on the preoperative 
findings or based on the intraoperative study of the hyster-
ectomy. Criteria indicative of low risk for nodal metastases 
are less than 50% of myometrial invasion, tumor less than 
2 cm or grade 1 and 2.
Table 1  Molecular features 
of endometrioid and serous 
endometrial cancer
EEC Endometrioid endometrial cancer, SC Serous carcinoma
Biomarker Alteration Frequency in EEC% Frequency 
in SC%
PTEN Loss of function 80 0–10
K-RAS Mutation 25 4
CTNNB4/β-catenin Mutation/nuclear expression 40 0–5
MI Microsatellite instability 20–45 0–5
PIK3CA Mutation 50 40
ER, PR Expression 70–73 20–24
ARID1A Mutation/loss of function 35 7
Stathmin Overexpression 15 64
HER 2 Overexpression 3–10 32
E-cadherin Loss of function 5–50 60–90
P16 Loss of function 8 45
P53 Mutation 11 80–90
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Sentinel lymph node mapping (SLNM) provides impor-
tant information to tailor adjuvant therapy and reduces LND-
related morbidity and long-term sequelae of unnecessary 
adjuvant treatments, although published results are single-
institution series or multi-institutional collaborations, with-
out a prospective randomized trial.
Laparoscopic approach has a lower rate of surgical com-
plications and similar outcomes than laparotomy. Robotic 
approach could be an alternative to laparoscopic approach, 
with less estimated blood loss and outcomes comparable to 
laparoscopy.
In non-endometrioid early stages, due to their high pro-
pensity to disseminate in the upper abdomen, complete 
staging including abdominal cavity review, bilateral sal-
pingo-oophorectomy, pelvic lymphadenectomy, para-aortic 
lymphadenectomy up to the renal vein, omentectomy and 
peritoneal biopsies with maximal surgical debulking is 
recommended.
The standard surgical approach of endometrioid EC in 
early stages is laparoscopic [I, A] with total hysterectomy, 
without vaginal cuff and bilateral salpingo-oophorectomy 
[IA]. In low-risk EC, LND is not recommended [II, A]. In 
intermediate and high-risk group, LND is recommended to 
guide surgical staging and adjuvant therapy [II, C]. SLNM 
in EC is promising and being performed in many centers, but 
still can not be recommended as standard treatment. In non-
endometrioid early stages, complete staging and maximal 
surgical debulking is recommended [IV, A].
Advanced stages
A complete staging with maximal surgical debulking is rec-
ommended in patients with good performance status and 
resectable tumor [III, B]. Palliative surgery could be consid-
ered in patients with good performance status and metastasic 
disease [IV, A].
Fertility sparing therapy
Reproductive age women with low-risk EC should be 
advised about fertility sparing options. To recommend fer-
tility preservation, it is important to exclude evidence of 
myometrial invasion, extrauterine disease or non-endome-
trioid histologies. Progestin therapy (medroxyprogesterone 
acetate; 400–600 mg/day or megestrol acetate; 160–320 mg/
day or an intrauterine device containing levonorgestrel) is 
the only available option in these patients, but there are no 
studies that compare progestin therapy vs standard therapy. 
Close follow-up and confirmation of lesion regression are 
mandatory.
Table 3  ESMO risk groups to 
guide adjuvant therapy use
LVSI lymphovascular invasion, EEC endometrioid endometrial cancer, EC endometrial cancer
Risk group Description
Low risk Stage I endometrioid G1–2, < 50% myometrial invasion, LVSI negative
Intermediate risk Stage I endometrioid, G1–2, ≥ 50% myometrial invasion, LVSI negative
High–intermediate risk Stage I endometrioid, G3, < 50% myometrial invasion regardless of LVSI
Stage I G1–2, LVSI positive, regardless of depth of invasion
High risk Stage I EEC, G3, ≥ 50% myometrial invasion, regardless of LVSI
Stage II EEC
Stage III EEC optimally debulked
Non-endometrioid EC (serous or clear cell or undifferentiated carcinoma, 
or carcinosarcoma)
Table 2  FIGO classification 
2009
Stage Definition
IA Tumor confined to the uterus, no or < ½ myometrial invasion
IB Tumor confined to the uterus, > ½ myometrial invasion
II Cervical stromal invasion, but not beyond the uterus
IIIA Tumor invades serosa or adnexa
IIIB Vaginal and/or parametrial involvement
IIIC1 Pelvic node involvement
IIIC2 Para-aortic involvement
IVA Tumor invades bladder and/or bowel mucosa
IVB Distant metastases including abdominal metastases and/or 
inguinal lymph nodes
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Fertility preservation could be offered in reproductive age 
patients with low-risk EC, but there is no standard option 
[V, A]. Progestins are the recommended treatment [IV, B].
Adjuvant treatment
Adjuvant treatment for patients with early-stage disease is 
tailored according to the risk group and the most important 
prognostic factors.
Adjuvant radiotherapy
Pelvic radiation (PRT) after surgery in stage I EC provides 
locoregional control, but there is no improvement in OS or 
disease-free survival (DFS) [10]. A randomized trial com-
paring vaginal brachytherapy (VBT) and observation in 
women with stage IA, grade 1 and 2 endometrioid EC have 
shown no OS benefit in VBT group and VBT was associated 
with an increase in genitourinary symptoms [11]. The results 
of PORTEC-2 trial, that compared VBT and PRT [12] in 
the high–intermediate-risk group, showed that there were 
no differences in pelvic or vaginal recurrences, DFS and 
distant metastasis, but the VBT group suffered significantly 
lesser toxicities than the PRT group. VBT in combination 
with PRT was compared to VBT only in patients with inter-
mediate risk in a randomized trial [13]. Addition of PRT 
improved locoregional control, but had no impact on OS and 
was associated with increased acute gastrointestinal and uri-
nary toxicity. Postoperative RT has been considered standard 
in high-risk EC group, although a comparative study of adju-
vant radiation versus no treatment in this group of patients 
has not been conducted.
Adjuvant chemotherapy
Results of prospective randomized trials comparing PRT to 
chemotherapy (CT) in high-risk EC have shown that CT 
reduced the risk of distant recurrences, but did not improve 
OS and the local control was poor. These observations have 
provided the rationale for a combined CT/RT approach. 
The role of adjuvant combined treatment with PRT and CT 
in EC has been studied in patients with intermediate and 
high risk. The pooled analysis of NSGO-EC-9501/EORTC-
55991 and MaNGO ILIADE-III trials demonstrate that com-
bined treatment (four cycles of platinum-based CT, given 
either before or after RT) improve DFS and show a trend 
towards improved OS [14]. The limitation of these studies 
is that 25–40% of the patient population was stage III or 
incompletely surgically staged. The type of CT used and the 
number of cycles are other concerns that preclude generali-
zation of these results.
The recent results of the two randomized trials have 
shown no benefit for adjuvant CT over PRT in high–inter-
mediate and high-risk EC. In PORTEC-3 trial, PRT was 
compared with chemoradiation (two cycles of cisplatin with 
PRT, followed by four cycles of carboplatin and paclitaxel), 
with no difference in OS or DFS, but adverse events were 
more frequent with CT/RT. However, in stage III, there was 
an improvement in DFS with CT/RT with no improvement 
in OS [15]. In GOG 249, CT (carboplatin-paclitaxel) plus 
VBT have demonstrated similar DFS as PRT, but more acute 
toxicity [16]. The results of GOG 258, a randomized trial 
that compared CT vs CT-RT in stages III to IVA, I–II serous 
or clear cell EC have shown no differences in DFS [17]. In 
PORTEC-3 and GOG 258, completion rate of CT was lower 
after radiation and most recurrences were distant. For these 
reasons, in stage III EC, we recommend adjuvant CT fol-
lowed by PRT, rather than the combination. The results of 
protocol ENGOT-EN2-DCGC will definitively address the 
benefit of chemotherapy in high-risk early stages.
Adjuvant treatment recommendations with the level of 
evidence and grade of recommendations are summarized 
in Fig. 1.
Treatment of metastatic and advanced 
disease
Surgery or radiation (in non-irradiated area) are options 
in patients with isolated centropelvic recurrence or single 
metastasic site [IV, A]. In patients with extrapelvic relapse, 
CT or hormonal therapy (HT) are palliative options.
Hormonal treatment
HT could be an option in endometrioid EC. The response 
rate (RR) with progestagens in first line is ~ 25%, while 
the RR described with tamoxifen or aromatase inhibi-
tors is ~ 10%. Predictors of response are low histological 
grade, prolonged time to relapse, the location and extent of 
extrapelvic disease and positive hormone receptor. Hormone 
receptor status should be determined before initiating hor-
monal therapy, although its role as a predictor of response to 
hormonal treatment has not been clearly demonstrated [18]. 
The treatment of choice is a progestational agent (megestrol 
acetate 160 mg QD or medroxyprogesterone acetate 200 mg 
QD) [III, A].
Endocrine therapy is recommended as a therapeutic alter-
native for those patients with G1–2 tumors, hormone recep-
tor positive and no rapid progressive disease [IV, A].
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Low risk EEC
(stage I G1-2, <50% myometrial invasion, 
LVSI negative)
No adjuvant treatment [I,A]
Intermediate risk




(stage I, G3, < 50% myometrial invasion regardless of LVSI or
Stage I G1-2, LVSI positive, regardless of depth of invasion)
Surgical nodal staging performed, node negative
Adjuvant VBT [III,B] +/- CT [III,B]  
No surgical node staging
LVSI positive: Adjuvant PRT  [III,B] +/- CT [III,B]
G3 or LVSI negative: Adjuvant VBT [III,B]+/- CT [III,B] 
High risk
Stage I EEC
( G3, ≥ 50% myometrial invasion, regardless of 
LVSI )
Stage II EEC
Surgical nodal staging performed, node negative
Adjuvant PRT  [I,B] or VBT [III,B] +/- CT [III,B]
No surgical node staging
Adjuvant PRT  [III,B] +/- CT [III,B]
Stage III EEC optimally debulked Adjuvant CT followed by PRT[I,A]
Non endometrioid EC
Stage IA,LVSI negative Adjuvant VBT[III,B]
Stage III optimally 
debulked
Adjuvant CT followed 
by PRT
[I,A]
Stage IB and II Adjuvant PRT  [III,B]
Fig. 1  Adjuvant treatment for endometrial cancer. LVSI lymphovascu-
lar invasion, VBT vaginal brachytherapy, CT chemotherapy, PRT pel-
vic radiotherapy, EEC endometrioid endometrial cancer, EC endome-
trial cancer. Modified from endometrial cancer algorithms that refers 
to Colombo et al. [7]
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Chemotherapy
The most active drugs in EC are doxorubicin, platinum 
agents and paclitaxel. Doxorubicin was compared with 
doxorubicin plus cisplatin (AP) in FIGO III and IV EC in 
two large randomized trials. The combination arm showed 
better RR and PFS, but no benefit in OS. Doxorubicin 
plus paclitaxel combination was compared to AP, and no 
significant differences were found in RR, DFS or OS. AP 
combination was compared with doxorubicin, cisplatin and 
paclitaxel (TAP) in advanced EC, with an improvement in 
RR, PFS and OS that was shown in the TAP arm, but with 
bad tolerability [19]. The GOG 209 trial compared carbopl-
atin–paclitaxel (CT) versus TAP. There were no differences 
in OS or DFS (in the CT arm: PFS 12–14 m, OS 32 m). The 
better toxicity profile of CT regimen made it the standard 
scheme for advanced disease, but also for adjuvant treat-
ment [20].
Available options after the first-line therapy are limited. 
The evaluated drugs are paclitaxel (RR 20%), liposomal 
doxorubicin (RR 9.5%), ifosfamide (RR 15%), oxaliplatin 
(RR 13. %) and ixabepilone (RR 12%).
Carboplatin and paclitaxel is the standard option in meta-
static or advanced endometrial cancer [I, A]. There is no 
standard CT for second line.
Table 4  SEOM guidelines recommendations for the management of endometrial cancer
Diagnosis
 TVUS and endometrial sampling should be considered the standard approach [II, B]
 Women with EC should have contrast-enhanced MRI and chest RX before surgery [IV, A]
Hereditary endometrial guidelines
 Molecular screening for LS should be performed in women with Amsterdam or Bethesda criteria and women with EC before 50 years [II, 
A]. Prophylactic surgery with hysterectomy and bilateral salpingo-oophorectomy should be offered in women with LS mutations who have 
completed childbearing [IV, B]
Screening
 Routine screening of asymptomatic women at average or increased risk of endometrial carcinoma is not recommended [II, A]
Staging
 EC is surgically staged. The staging is based on FIGO 2009 [IV, A]
Surgical treatment
 The standard surgical approach of endometrioid EC in early stages is laparoscopic [I, A] with total hysterectomy without vaginal cuff and 
bilateral salpingo-oophorectomy [IA]. In low-risk EC LND is not recommended [II,A]. In intermediate and high-risk group, LND is recom-
mended to guide surgical staging and adjuvant therapy [II, C]. SLNM in EC is still not recommended as standard treatment. In non-endome-
trioid early stages, complete staging and maximal surgical debulking is recommended [IV, A]
 In advanced stages, a complete staging with maximal surgical debulking is recommended in patients with good performance status and resect-
able tumor [III, B]. Palliative surgery could be considered in patients with good performance status and metastasic disease [IV, A]
 Fertility preservation could be offered in reproductive age patients with low-risk EC, but there is no the standard option [V, A]. Progestins are 
the recommended treatment [IV, B]
Adjuvant treatment
 Low-risk patients do not require adjuvant treatment [I, A]
 VBT is recommended for intermediate-risk patients [I, A]
 In the intermediate–high-risk group, VBT is recommended in patients with surgical staging and node negative [III, B]. CT can be evaluated 
[III, B]. In patients with no surgical nodal staging, PRT and VBT is recommended [III, B]
 In high-risk early stages, endometrioid EC, VBT [III, B] or PRT [III, B] are recommended. In early stages with non-endometrioid histologies 
VBT [IIIB] or PRT [I, B],CT can be evaluated [III, B]. The recommendation in stage III optimally debulked is CT, followed by PRT [I, B]
Treatment of advanced or recurrent disease
 Surgical or local treatment (radiation in non-irradiated area) are options in patients with isolated centropelvic recurrence or single metastasic 
site [IV, A]
 Endocrine therapy is recommended as a therapeutic alternative for those patients with well-differentiated tumors or a long disease-free interval 
[IV, A]
 Carboplatin and paclitaxel is the standard option in metastatic or advanced endometrial cancer [I, A]. There is no standard CT for second line
Follow-up
 Physical examination with a thorough speculum, pelvic, and rectovaginal examination is the most effective method for the detection of EC 
recurrences [IV, A]
 Cytology evaluation and chest RX are not recommended in asymptomatic women, imaging test should be reserved for patients with suspected 
recurrence [IV, A]
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Targeted therapies
The identification of molecular abnormalities in EC, as 
described previously, has permitted the development of new 
drugs as target therapies. Antiangiogenic drugs and mTOR/
PI3K inhibitors are the most promising agents. EGFR and 
Her-2 neu inhibitors have had disappointing results. Up to 
now, no approved targeted therapies are available for EC.
Antiangiogenic drugs
Bevacizumab has been evaluated as a monotherapy agent 
in phase II trials, resulting in a RR of 15.1%, PFS 4.2 
and OS 10.5 months and, in combination with paclitaxel 
and carboplatin with a RR of 73%. Latest phase II rand-
omized trials (GOG86P and MITO END-2) have shown 
an interesting activity in combination with carboplatin and 
paclitaxel in first line, in advanced or metastatic EC [21, 
22]. Phase III trials with bevacizumab combination are 
ongoing.
mTOR inhibitors
Several phase II trials have been reported with mTOR 
inhibitors. The largest randomized study observed a PFS 
of 3.6 months for the experimental arm versus 1.9 months 
for the hormonotherapy treatment group. These drugs 
have shown low RR (0–25%), but the clinical benefit is 
secondary to long disease stabilization. Preclinical data 
have suggested that mTOR inhibition reverses hormonal 
resistance. A phase II trial with letrozole and everolimus 
has been reported with 32% of RR.
Follow‑up
Most EC relapses occur within 3 years after primary treat-
ment. The pelvis is the most common site of recurrence, 
most of them in the vaginal vault, whereas distant relapses 
account for only one-third of all the cases. Most patients 
with EC will have a low risk of recurrence and more than 
one-half of all the recurrences will be detected with exami-
nation and symptoms. Recurrent EC has poor prognosis, 
regardless of the time of detection, with the exception of 
local relapse.
There are no prospective studies that have evaluated 
the role of the surveillance in EC. The most consistently 
used method is the physical examination which includes 
a thorough speculum, pelvic, and rectovaginal examina-
tion. Cytology does not add any clinical benefit [23]. The 
CA-125 level should not be used routinely in patients 
with EC, but may be appropriate in selected patients with 
advanced disease, serous histology or a higher CA-125 
level at diagnosis [24]. The routine use of chest RX is not 
recommended. Pelvic US and CT may play a role in the 
evaluation of patients with symptoms, advanced stages or 
clinical signs of recurrence.
All recommendations for the diagnosis, treatment and 
follow-up of EC are summarized in Table 4.
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